Drugs / MT-2111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05658562 | Jan 2023 → Aug 2028 expected | diffuse large B-cell lymphoma | Tanabe Pharma Corporation | Active not recruiting | Met primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-29 | Tanabe Pharma Corporation | MT-2111 (loncastuximab tesirine-lpyl) Achieved Primary Endpoint in Phase 2 part of Japanese Phase 1/2 study for Relapsed or Refractory Diffuse Large B-cell Lymphoma tanabe-pharma.com ↗ |
| 2023-10-25 | Tanabe Pharma Corporation | A Global Phase 3 Clinical Trial of MT-2111 in Combination with Rituximab has been started in Japan tanabe-pharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-2111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658562 ↗ |
| Route | Intravenous | “i.v. infusion” NCT05658562 ↗ |